Immunogen Q3 EPS $0.10 Beats $0.04 Estimate, Sales $113.42M Beat $106.04M Estimate
Portfolio Pulse from Benzinga Newsdesk
Immunogen (NASDAQ:IMGN) reported Q3 earnings of $0.10 per share, beating the analyst consensus estimate of $0.04 by 150%. This is a 132.26% increase over losses of $(0.31) per share from the same period last year. The company also reported quarterly sales of $113.42 million, beating the analyst consensus estimate of $106.04 million by 6.96%. This is a 637.72% increase over sales of $15.38 million the same period last year.
November 02, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunogen's Q3 earnings and sales significantly beat estimates, indicating strong financial performance.
Immunogen's Q3 earnings and sales have significantly exceeded estimates, indicating a strong financial performance. This is likely to increase investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100